HIV-1 infection alters energy metabolism in the brain:contributions to HIV-associated neurocognitive disorders, 2019, Cotto et al

Andy

Retired committee member
Highlights

Abnormal brain metabolic profiles of people living with HIV-1 coincide with cognitive deficits.
HIV-associated stressors (viral particles, viral proteins and cytokines) directly disrupt normal glial metabolism that compromises their ability to support neuronal metabolism.

Additional factors such as combination antiviral therapy, aging and substance abuse can exacerbate HIV-associated metabolic disturbances and accelerate disease progression.

Abstract
The brain is particularly sensitive to changes in energy supply. Defects in glucose utilization and mitochondrial dysfunction are hallmarks of nearly all neurodegenerative diseases and are also associated with the cognitive decline that occurs as the brain ages. Chronic neuroinflammation driven by glial activation is commonly implicated as a contributing factor to neurodegeneration and cognitive impairment. Human immunodeficiency virus-1 (HIV-1) disrupts normal brain homeostasis and leads to a spectrum of HIV-associated neurocognitive disorders (HAND). HIV-1 activates stress responses in the brain and triggers a state of chronic neuroinflammation.

Growing evidence suggests that inflammatory processes and bioenergetics are interconnected in the propagation of neuronal dysfunction. Clinical studies of HIV-infected individuals and basic research support the notion that HIV-1 creates an environment in the CNS that interrupts normal metabolic processes at the cellular level and collectively alter whole brain metabolism. In this review, we highlight reports of abnormal brain metabolism from clinical studies and animal models. We also describe diverse CNS cell-specific changes in bioenergetics associated with HIV-1. Moreover, we propose that attention should be given to adjunctive therapies that combat sources of metabolic dysfunction as a mean to improve and prevent neurocognitive impairments.
Paywall, https://www.sciencedirect.com/science/article/pii/S0301008218302168
Sci hub, https://sci-hub.se/10.1016/j.pneurobio.2019.101616
 
Well that was depressing reading for someone living with HIV.

Save this: "...implementation of a ketogenic diet [88, 212, 213], intranasal insulin treatment [214], or exercise [215] coupled with use of anti-inflammatory drugs may provide therapeutic benefits to PLWH."
 
Well that was depressing reading for someone living with HIV.

Save this: "...implementation of a ketogenic diet [88, 212, 213], intranasal insulin treatment [214], or exercise [215] coupled with use of anti-inflammatory drugs may provide therapeutic benefits to PLWH."

The good news is that both factors contributing to HIV-associated Neurocognitive Disorder (HAND) can be mitigated by a careful choice of antiretroviral medication.

There are many of these such papers that make it sound like HAND is an inevitable consequence of HIV infection. It is not. I have read many of these papers, and they conflate quite different antiretroviral regimens and do not discriminate between PLWH who had HIV for many years before the advent of HAART and those who received HAART soon after seroconversion.

The two main factors that contribute to HAND are 1) the inability of an antiretroviral drug to penetrate the blood-brain barrier and 2) a negative impact of the antiretroviral drug on mitochondria. The ideal antiretroviral regimen will include at least 2 drugs that penetrate the blood brain barrier well, and no drugs with a significant negative impact on mitochondria.

Unfortunately, the widely disseminated treatment guidelines do not take these factors into account. Firstly, the treatment guidelines were based entirely on which antiretroviral drugs best reduce virus in the blood, with absolutely no consideration given to whether or not the drugs cross the blood-brain barrier. Secondly, the determination of which drugs negatively affect mitochondria were based on limited assays that only tested the drugs against the few mitochondrial proteins that were impacted by earlier generations of antiretroviral drugs. (AZT, ddI, d4t)

As a result of this short-sighted thinking, we still do not have sufficient research about which antiretroviral drugs cross the blood-brain barrier well, with conflicting results for even the most popular antiretrovirals. And we have misconceptions about the potential mitochondrial toxicity of some antiretrovirals. For example, Abacavir is widely held to be one of the safest antiretrovirals for mitochondria, since it showed virtually no inhibition of the mitochondrial proteins that were inhibited by earlier generations of antiretrovirals. Subsequent research that tested Abacavir against whole mitochondria, however, found significant toxicity.
 
Very interesting @Pyrrhus - I did not know there was such lack of clarity about ARVs and BBB and mitochondria, thanks for the info - makes me question my own regimen.

Segue slightly: I know lots of pwHIV yet do not know any with ME diagnosis (post-HIV). Are you aware of any, come across any research indicating such?
 
Segue slightly: I know lots of pwHIV yet do not know any with ME diagnosis (post-HIV). Are you aware of any, come across any research indicating such?

I don’t know of any pwHIV who developed ME post-HIV. I vaguely remember Dr. Chia mentioning that of the thousands of ME patients he had seen, about 4-5 of them had HIV.

But it’s important to remember that many of the ME diagnostic criteria consider HIV to be an exclusionary criterion. This means that doctors were prohibited from diagnosing ME by these diagnostic criteria if the patient tested positive for HIV.
 
Last edited:
But it’s important to remember that many of the ME diagnostic criteria consider HIV to be an exclusionary criterion. This means that doctors were prohibited from diagnosing ME by these diagnostic criteria if the patient tested positive for HIV.

I did not realize that. Presumably HIV is not the only exclusionary illness from getting a ME diagnosis.

I wonder how many people with an 'exclusionary' illness and ME symptoms, and do not get the ME diagnosis?
 
The point about exclusionary illnesses is that the illness would be expected to cover everything. It does not mean that if you have one you can't get the other. For instance if you have MS then feeling very fatigued is covered by the MS diagnosis you do not need to have CFS as well.

However if you develop PEM say then you may have ME as well as MS.

The problem is the diagnostic confusion that exists with ME and CFS and the lack of clear diagnostic tests. If you have had ME for 20 years then test positive for HIV you could have both but it would be harder to say you have acquired ME after having had HIV for 20 years.

Things are made worse by CFS being used to describe the symptom of fatigue nowadays.
 
Back
Top Bottom